TICKERNERD
Menu
FATEFATEHealthcare · Biotechnology

FATE Stock Forecast: Fate Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$2.17
+4.83% on the day

The 11 Wall Street analysts covering Fate Therapeutics, Inc. hold a median 12-month price target of $7 — +222.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 28 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$248.0M
Ticker Nerd rank
96/ 100
Median analyst target
$7.00
Analysts covering
11
Revenue$2.1M+9.2% y/y
Operating income−$31.1M
Net income−$30.2M
Free cash flow−$23.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.8%
1M
−8.8%
YTD
+121.4%
1Y
+45.6%
From 52W high
−30.2%
From 52W low
+126.0%
$0.96
$3.11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FATE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Fate Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
96/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
95
Momentum
88
Accruals
81
Revisions
78
Issuance
72
Quality
67
Size
63
Value
61
Volatility
21

Growth (95): Sales and profits are climbing, and climbing faster than before.

Volatility (21): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

FATE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FATE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26FATEHigh $8.00Median $7.00Low $2.20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
5 Buy6 Hold0 Sell
Low $2.20Median $7.00High $8.00

The green dot is the last close — the median target sits +222.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Oct 2026WedbushReiteratesOutperform$7.00
14 Aug 2026Piper SandlerReiteratesOverweight$6.00 → $8.00
14 Aug 2026Piper SandlerReiteratesOverweight—
14 Aug 2026WedbushReiteratesOutperform—
14 Aug 2026WedbushReiteratesOutperform$7.00
14 Aug 2026Wells FargoMaintainsEqual-Weight$2.50 → $3.50
14 Aug 2026Wells FargoMaintainsEqual-Weight—
8 June 2026HC Wainwright & Co.ReiteratesBuy$7.00
8 June 2026HC Wainwright & Co.ReiteratesBuy—
4 May 2026HC Wainwright & Co.MaintainsBuy—
31 Oct 2025HC Wainwright & Co.UpgradeBuy—
27 Oct 2025NeedhamReiteratesHold—
27 Oct 2025WedbushUpgradeOutperform—
13 Aug 2025Wells FargoMaintainsEqual-Weight—
12 June 2025NeedhamReiteratesHold—
14 May 2025BairdMaintainsNeutral—
14 May 2025BarclaysMaintainsOverweight—
14 May 2025NeedhamReiteratesHold—
6 Mar 2025NeedhamReiteratesHold—
6 Mar 2025StifelMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

FATE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

FATE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Fate Therapeutics, Inc. returned +45.6% against +13.6% for the S&P 500, dividends included.

FATE vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26FATES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FATE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
2
Fundamentals

Fate Therapeutics, Inc. (FATE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.8×

Cheaper than 86% of US stocks

Price / sales
38.2×

Cheaper than 6% of US stocks

Price / book
1.6×

Cheaper than 51% of US stocks

EV / EBITDA
−1.4×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
9.2%

Higher than 51% of US stocks

Earnings growth (YoY)
9.2%

Higher than 47% of US stocks

Gross margin
—
Operating margin
−1495.4%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−60.8%

Higher than 19% of US stocks

Return on assets
−26.2%

Higher than 16% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Fate Therapeutics, Inc. (FATE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Fate Therapeutics, Inc. has a market value of $248.0M and an enterprise value of $169.9M.

  • Revenue in the twelve months to 30 June 2026: $6.5M. The latest quarter grew 9.2% year on year.

  • Net income over the same four quarters: −$126.0M, a −1941.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.05.

  • Free cash flow in the twelve months to 30 June 2026: −$105.7M.

  • Shares outstanding: 116.7M.

  • Trailing P/E: −1.8×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Fate Therapeutics, Inc. employs 161 people — $40K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

FATE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FATEFate Therapeutics, Inc.$248.0M96
IFRXInflaRx NV$254.8M9
CABACabaletta Bio, Inc.$247.8M21
IMRXImmuneering Corp.$257.6M36
LXEOLexeo Therapeutics, Inc.$245.8M27
LCTXLineage Cell Therapeutics, Inc.$259.1M61
ABEOAbeona Therapeutics, Inc.$259.6M43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Fate Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FATE news & analysis

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

GlobeNewsWire · 26 Oct 2026positive

Fate Therapeutics presented updated preliminary Phase 1 data for FT819 in active lupus nephritis at ASN Kidney Week 2026. Patients given FT819 with the less-intensive bendamustine conditioning regimen had a 100% renal response at Month 6 and an approximately 50% mean reduction in proteinuria; no dose-limiting toxicities, high-grade CRS, ICANS, GvHD, or IEC-HS were reported.

Why it matters — The data provide an update on FT819’s safety and renal response in lupus nephritis as the company continues its Phase 2 RECLAIM-LN study.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 2 Oct 2026neutral

Fate Therapeutics announced that on October 1, 2026, it granted non-qualified stock options to one newly-hired non-executive employee for 62,900 shares at a $2.30 exercise price, and RSUs representing 72,700 shares to two newly-hired non-executive employees. The awards were approved by the Compensation Committee under the company's Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4), with vesting over four years.

Why it matters — This disclosure of inducement equity grants offers FATE watchers routine insight into new-hire compensation and share dilution under Nasdaq rules, without indicating any change in the company's operational or clinical outlook.

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

GlobeNewsWire · 1 Oct 2026neutral

Fate Therapeutics announced that its management will participate in several upcoming investor conferences during the fourth quarter of 2026. The clinical-stage biopharmaceutical company focuses on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases.

Why it matters — The conference participation gives investors opportunities to hear directly from FATE management about its iPSC-derived immunotherapy pipeline.

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

GlobeNewsWire · 25 Sept 2026positive

Fate Therapeutics announced receipt of a $15.0 million California Institute for Regenerative Medicine (CIRM) CLIN2 grant to support advancement of RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 off-the-shelf CAR T-cell therapy in lupus nephritis.

Why it matters — The grant provides non-dilutive funding that supports the clinical advancement of a potentially registrational trial for Fate's off-the-shelf CAR T-cell therapy in lupus nephritis.

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

GlobeNewsWire · 16 Sept 2026positive

Fate Therapeutics announced that four abstracts from its off-the-shelf CAR T-cell programs were selected for presentation at the American College of Rheumatology (ACR) Convergence 2026, held November 6-11 in Orlando, Florida. The presentations will highlight the company's iPSC-derived cellular immunotherapy portfolio in autoimmune disease.

Why it matters — This selection increases visibility of FATE's off-the-shelf CAR T-cell programs in the autoimmune disease setting and signals potential upcoming clinical data at a major rheumatology conference.

FAQ

Frequently asked questions about FATE stock

What is the FATE stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Fate Therapeutics, Inc. have a median 12-month price target of $7, with estimates ranging from $2.2 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FATE stock a buy right now?

Of the 11 analysts covering Fate Therapeutics, Inc., 5 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Fate Therapeutics, Inc. 96 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FATE?

As at 28 Oct 2026, Fate Therapeutics, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (95 of 100).

Will FATE stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +222.6% from the last close, and Ticker Nerd's factor model ranks Fate Therapeutics, Inc. 96 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FATE stock forecast for 2030?

No analyst covering Fate Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FATE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.2 to $8 over the next 12 months.

How has FATE stock performed over the past year?

Fate Therapeutics, Inc. returned +45.6% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Fate Therapeutics, Inc. do?

Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune-related diseases.

What is the latest news on FATE?

The most recent item we track (GlobeNewsWire, 26 Oct 2026): "Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026". Fate Therapeutics presented updated preliminary Phase 1 data for FT819 in active lupus nephritis at ASN Kidney Week 2026. Patients given FT819 with the less-intensive bendamustine conditioning regimen had a 100% renal response at Month 6 and an approximately 50% mean reduction in proteinuria; no dose-limiting toxicities, high-grade CRS, ICANS, GvHD, or IEC-HS were reported.

Company

About Fate Therapeutics, Inc.

Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune-related diseases. The company uses its proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf cell therapy candidates, including natural killer (NK) cell and T-cell programs designed to address key limitations in traditional cell manufacturing. Its portfolio centers on immuno-oncology and immuno-regulatory applications, with product candidates aimed at treating solid tumors, blood cancers, and autoimmune disorders. Fate Therapeutics also applies its cell programming approach to engineer synthetic controls of cell function and produce renewable master cell lines for scalable development. Headquartered in San Diego, California, Fate Therapeutics plays a specialized role in the advanced cell therapy market, where it supports the transition from donor-derived treatments to more standardized, engineered therapeutic products.

CEO Dr. Bahram Valamehr M.B.A., Ph.D. · 161 employees · United States · https://www.fatetherapeutics.com